How NeoGenomics' Patent Victory Over Natera Could Reshape the MRD Market

U.S. District Court ruled in favor of NeoGenomics, invalidating two core Natera patents (11,530,454 and 11,319,596) in their Minimal Residual Disease testing dispute. The court deemed Natera's patents invalid for claiming "ineligible subject matter" based on natural phenomena without demonstrating an "inventive concept." This overturns Natera's 2023 injunction against NeoGenomics' RaDaR v1.0 product, allowing NeoGenomics to commercialize its RaDaR ST assay and pursue CMS reimbursement. NeoGenomics' stock surged 18% following the ruling. Natera retains other patents but faces diminished IP protection and reported $100.9 million net loss partly from legal costs.